Related Experiment Video
Updated: May 16, 2026
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Antitumor effect of metformin in esophageal cancer: in vitro study
Mitsuyoshi Kobayashi1, Kiyohito Kato, Hisakazu Iwama
1Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan.
Abstract:
Recent studies suggest that metformin, which is a member of the biguanide family and commonly used as an oral anti-hyperglycemic agent, may reduce cancer risk and improve prognosis of numerous types of cancer. However, the mechanisms underlying the antitumor effect of metformin on esophageal cancer remain unknown. The goal of the present study was to evaluate the effects of metformin on the proliferation of human ESCC in vitro, and to study changes in the expression profile of microRNAs (miRNAs), since miRNAs have previously been associated with the antitumor effects of metformin in other human cancers. The human ESCC cell lines T.T, KYSE30 and KYSE70 were used to study the effects of metformin on human ESCC in vitro. In addition, we used miRNA array tips to explore the differences between miRNAs in KYSE30 cells with and without metformin treatment. Metformin inhibited the proliferation of T.T, KYSE30 and KYSE70 cells in vitro. Metformin blocked the cell cycle in G0/G1 in vitro. This blockade was accompanied by a strong decrease of G1 cyclins, especially cyclin D1, as well as decreases in cyclin-dependent kinase (Cdk)4, Cdk6 and phosphorylated retinoblastoma protein (Rb). In addition, the expression of miRNAs was markedly altered with the treatment of metformin in vitro. Metformin inhibited the growth of three ESCC cell lines, and this inhibition may have involved reductions in cyclin D1, Cdk4 and Cdk6.
Insights
Metformin, an anti-hyperglycemic agent, inhibits esophageal cancer cell growth by blocking the cell cycle. This study explores metformin
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Metformin, a biguanide, is an oral anti-hyperglycemic agent with potential anticancer properties.
- The specific mechanisms of metformin's antitumor effects on esophageal cancer are not well understood.
- MicroRNAs (miRNAs) are implicated in metformin's anticancer effects in other cancer types.
Purpose of the Study:
- To investigate the in vitro effects of metformin on human esophageal squamous cell carcinoma (ESCC) proliferation.
- To analyze changes in miRNA expression profiles in response to metformin treatment in ESCC cells.
Main Methods:
- Human ESCC cell lines (T.T, KYSE30, KYSE70) were treated with metformin in vitro.
- Cell proliferation and cell cycle progression were assessed.
- miRNA expression profiling was performed using array technology on KYSE30 cells.
Main Results:
- Metformin significantly inhibited the proliferation of all three tested ESCC cell lines.
- Metformin induced a G0/G1 cell cycle arrest.
- This arrest correlated with decreased expression of G1 cyclins (especially cyclin D1), cyclin-dependent kinases (Cdk4, Cdk6), and phosphorylated retinoblastoma protein (Rb).
Conclusions:
- Metformin demonstrates direct antitumor effects on human ESCC cells in vitro.
- The inhibition of ESCC cell growth by metformin may be mediated by the downregulation of key cell cycle regulators like cyclin D1, Cdk4, and Cdk6.
- Metformin treatment significantly alters miRNA expression profiles in ESCC cells, suggesting a role for miRNAs in its anti-esophageal cancer mechanisms.
